Personalis (NASDAQ:PSNL) Coverage Initiated at Craig Hallum

Craig Hallum assumed coverage on shares of Personalis (NASDAQ:PSNL) in a research report report published on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $8.00 price target on the stock.

Several other brokerages have also issued reports on PSNL. Needham & Company LLC reduced their price target on Personalis from $7.25 to $7.00 and set a “buy” rating for the company in a report on Friday, February 28th. Lake Street Capital lifted their price target on Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Personalis in a report on Friday, February 28th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $7.80.

Personalis Price Performance

NASDAQ:PSNL opened at $3.80 on Monday. The stock has a market cap of $335.40 million, a PE ratio of -2.26 and a beta of 1.73. Personalis has a fifty-two week low of $1.14 and a fifty-two week high of $7.20. The stock’s 50-day moving average is $4.92 and its two-hundred day moving average is $4.90.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.09. The business had revenue of $16.80 million during the quarter, compared to analyst estimates of $15.48 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. On average, equities research analysts anticipate that Personalis will post -1.4 earnings per share for the current year.

Institutional Investors Weigh In On Personalis

Several institutional investors and hedge funds have recently added to or reduced their stakes in PSNL. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Personalis in the 4th quarter worth approximately $28,000. JPMorgan Chase & Co. lifted its holdings in shares of Personalis by 2,827.0% during the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock worth $34,000 after buying an additional 5,654 shares during the last quarter. Olympiad Research LP acquired a new position in shares of Personalis during the fourth quarter worth approximately $59,000. Alpine Global Management LLC acquired a new position in shares of Personalis during the fourth quarter worth approximately $60,000. Finally, SG Americas Securities LLC acquired a new position in shares of Personalis during the fourth quarter worth approximately $63,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.